Sasamoto, Naoko; Babic, Ana; Rosner, Bernard-A; Fortner, Renee-T; Vitonis, Allison-F; Yamamoto, Hidemi; Fichorova, Raina-N; Titus, Linda-J; Tjonneland, Anne; Hansen, Louise; Kvaskoff, Marina; Fournier, Agnes; Mancini, Francesca-Romana; Boeing, Heiner; Trichopoulou, Antonia; Peppa, Eleni; Karakatsani, Anna; Palli, Domenico; Grioni, Sara; Mattiello, Amalia; Tumino, Rosario; Fiano, Valentina; Onland-Moret, N-Charlotte; Weiderpass, Elisabete; Gram, Inger-T; Quirós, J-Ramón; Lujan-Barroso, Leila; Sánchez, Maria-Jose; Colorado-Yohar, Sandra; Barricarte-Gurrea, Aurelio; Amiano, Pilar; Idahl, Annika; Lundin, Eva; Sartor, Hanna; Khaw, Kay-Tee; Key, Timothy-J; Muller, David; Riboli, Elio; Gunter, Marc; Dossus, Laure; Trabert, Britton; Wentzensen, Nicolás; Kaaks, Rudolf; Cramer, Daniel-W; Tworoger, Shelley-S; Terry, Kathryn-L
(BMC, 2019-11-26)
BACKGROUND: Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. ...